NLSP logo

NLS Pharmaceutics AG (NLSP) Company Overview

Profile

Full Name:

NLS Pharmaceutics AG

Sector:

Healthcare

Industry:

Biotechnology

Country:

Switzerland

IPO:

January 29, 2021

Indexes:

Not included

Website:

http://nlspharma.com

Description:

NLS Pharmaceutics AG is a biopharmaceutical company focused on developing innovative treatments for central nervous system disorders. They aim to improve the lives of patients with conditions like narcolepsy and ADHD by creating new medications that are more effective and have fewer side effects.

Key Details

Price

$1.58

Market Cap

$6.03 M(Small cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$12.80(+61.90% YoY)

PE Ratio

-

Annual ROE

137.79%

Annual Debt To Equity

-0.18

Beta

0.05

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Jan 10, 2024

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Sep 27, 2024

Analyst ratings

Recent major analysts updates

Mar 12, 21 Brookline Capital
Buy
Mar 3, 21 Maxim Group
Buy

Screeners with NLSP included

Growing Shares Outstanding
Stocks below SMA 200
Stocks recommended to hold
Healthcare sector
All stocks
Biotechnology industry
Small cap stocks
Stocks with low beta
NASDAQ earnings calendar

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$1.58
NLSP price is $1.58

Price All-time High

$234.00
NLSP price is currently -99.32% below its historical high of $234.00

Price Analysts Target

-
NLSP price consensus analysts' forecast is unknown

Price Today Change

-0.52%
NLSP price is down -0.52% today

Price YTD Change

-21.7%
NLSP price is down -21.7% since January 1st

Price 3-Year Change

-97.23%
NLSP price is down -97.23% over the past 3 years

Market cap

Market Cap

$6.03 M
NLSP market capitalization is $6.03 million

Market Cap 3-Year Change

-73.99%
NLSP market capitalization is down -73.99% over the past 3 years

Market Cap All-time High

$68.98 M
NLSP market capitalization is currently -91.25% below its historical high of $68.98 million

Market Cap Sector Rank

13.99%
NLSP market capitalization is higher than 13.99% of companies in Healthcare sector

Technical

Beta

0.05
NLSP beta is 0.05

200-day SMA

$4.75
NLSP price is currently -66.72% below its 200-day simple moving average

14-day RSI

33.75
NLSP 14-day relative strength index is 33.75

30-day Relative Volume

0.98
NLSP 30-day relative volume is 0.98

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

-
NLSP annual revenue value is unknown

Annual Revenue Analysts Estimate

-
NLSP annual revenue consensus analysts' forecast is unknown

Annual Revenue 1-Year Change

-
NLSP annual revenue 1-year change is unknown

Annual Revenue Sector Rank

-
NLSP annual revenue is unknown

Profit

Annual Gross Profit

-
NLSP annual gross profit value is unknown

Annual Gross Margin

-
NLSP annual gross profit margin value is unknown

Annual Operating Profit

-$11.81 M
NLSP annual operating income is -$11.81 million

Annual Operating Margin

-
NLSP annual operating profit margin value is unknown

Annual Net Income

-$12.17 M
NLSP annual net profit is -$12.17 million

Annual Net Margin

-
NLSP annual net profit margin value is unknown

EPS

Annual EPS

-$12.80
NLSP annual earnings per share is -$12.80

Annual EPS Analysts Estimate

-$1.60
NLSP annual earnings per share is currently +700.00% higher than the consensus analysts' forecast

Annual EPS 1-Year Change

+61.9%
NLSP annual earnings per share is up +61.9% year-on-year

Annual EPS Sector Rank

13.3%
NLSP annual earnings per share is higher than 13.3% of companies in Healthcare sector

ROA & ROE

Annual ROA

-659.16%
NLSP annual return on assets is -659.16%

Annual ROE

137.79%
NLSP annual return on equity is 137.79%

EBIT & EBITDA

Annual EBIT

-$12.03 M
NLSP annual earnings before interest & taxes is -$12.03 million

Annual EBITDA

-$12.02 M
NLSP annual EBITDA is -$12.02 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
NLSP price to earnings ratio value is unknown

PE Ratio Sector Rank

-
NLSP price to earnings ratio is unknown

PB Ratio

PB Ratio

-0.65
NLSP price to book ratio is -0.65

PB Ratio Sector Rank

11.22%
NLSP price to book ratio is higher than 11.22% of companies in Healthcare sector

PS Ratio

PS Ratio

-
NLSP price to sales ratio value is unknown

PS Ratio Sector Rank

-
NLSP price to sales ratio is unknown

Enterprise value

Enterprise Value

$7.20 M
NLSP enterprise value is $7.20 million

Enterprise Value Sector Rank

20.84%
NLSP enterprise value is higher than 20.84% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-
NLSP EV/EBITDA value is unknown

EV/EBITDA Sector Rank

-
NLSP EV/EBITDA is unknown

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

0.23
NLSP annual current ratio is 0.23

Annual Quick Ratio

-
NLSP annual quick ratio value is unknown

Leverage

Annual Debt To Equity

-0.18
NLSP annual debt to equity ratio is -0.18

Annual Interest Coverage Ratio

-82.83
NLSP annual interest coverage ratio is -82.83

Risk & Stability

Piotroski F-Score

-
NLSP piotroski f-score value is unknown

Altman Z-Score

-
NLSP altman z-score value is unknown

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$1.85 M
NLSP annual total assets is $1.85 million

Annual Non Current Assets

$23.60 K
NLSP annual long term assets is $23.60 thousand

Annual Current Assets

$1.82 M
NLSP annual total current assets is $1.82 million

Annual Cash & Cash Equivalents

$897.70 K
NLSP annual cash & cash equivalents is $897.70 thousand

Equity

Annual Book Value

-$8.83 M
NLSP annual book value is -$8.83 million

Annual Working Capital

-$6.10 M
NLSP annual working capital is -$6.10 million

Liabilities

Annual Total Liabilities

$10.68 M
NLSP annual total liabilities is $10.68 million

Annual Total Long Term Liabilities

$2.76 M
NLSP annual total long term liabilities is $2.76 million

Annual Current Liabilities

$7.92 M
NLSP annual total current liabilities is $7.92 million

Annual Accounts Payable

$4.63 M
NLSP annual accounts payable is $4.63 million

Debt

Annual Total Debt

$1.63 M
NLSP annual total debt is $1.63 million

Annual Total Debt 1-Year Change

+100%
NLSP annual total debt is up +100% year-on-year

Annual Long Term Debt

-
NLSP annual long term debt value is unknown

Annual Short Term Debt

$1.63 M
NLSP annual short term debt is $1.63 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$11.81 M
NLSP annual total expenses is $11.81 million

Annual Operating Expenses

$11.81 M
NLSP annual total operating expenses is $11.81 million

Annual Cost Of Goods Sold

-
NLSP annual cost of goods sold value is unknown

Annual SGA

$5.90 M
NLSP annual SGA is $5.90 million

Annual D&A

$11.40 K
NLSP annual depreciation & amortization is $11.40 thousand

Annual Interest Expense

$145.20 K
NLSP annual interest expense is $145.20 thousand

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

-$9.68 M
NLSP annual cash flow from operations is -$9.68 million

Annual CFO 1-Year Change

+30.22%
NLSP annual cash flow from operations is up +30.22% year-on-year

Annual CFI

$0.00
NLSP annual cash flow from investing activities is $0.00

Annual CFI 1-Year Change

0%
NLSP {parameterFullLabel} has remained unchanged year-on-year

Annual CFF

$1.63 M
NLSP annual cash flow from financing activities is $1.63 million

Annual CFF 1-Year Change

-90.61%
NLSP annual cash flow from financing activities is down -90.61% year-on-year

Free CashFlow

Annual FCF

-$9.68 M
NLSP annual free cash flow is -$9.68 million

Annual FCF 1-Year Change

+30.22%
NLSP annual free cash flow is up +30.22% year-on-year

CAPEX

Annual CAPEX

-
NLSP annual capital expenditures value is unknown

Annual CAPEX 1-Year Change

-
NLSP annual capital expenditures 1-year change is unknown

Institutional Ownership

Similar stocks

VRAX logo
Virax Biolabs Group Limited (VRAX)
SBFM logo
Sunshine Biopharma (SBFM)
AMIX logo
Autonomix Medical (AMIX)
Dogwood Therapeutics (DWTX)
XBIO logo
Xenetic Biosciences (XBIO)
CYCN logo
Cyclerion Therapeutics (CYCN)
BIAF logo
bioAffinity Technologies (BIAF)
EVOK logo
Evoke Pharma (EVOK)
SILO logo
Silo Pharma (SILO)

FAQ

  • What is the ticker symbol for NLS Pharmaceutics AG?
  • Does NLS Pharmaceutics AG pay dividends?
  • What sector is NLS Pharmaceutics AG in?
  • What industry is NLS Pharmaceutics AG in?
  • What country is NLS Pharmaceutics AG based in?
  • When did NLS Pharmaceutics AG go public?
  • Is NLS Pharmaceutics AG in the S&P 500?
  • Is NLS Pharmaceutics AG in the NASDAQ 100?
  • Is NLS Pharmaceutics AG in the Dow Jones?
  • When was NLS Pharmaceutics AG's last earnings report?
  • When does NLS Pharmaceutics AG report earnings?
  • Should I buy NLS Pharmaceutics AG stock now?

What is the ticker symbol for NLS Pharmaceutics AG?

The ticker symbol for NLS Pharmaceutics AG is NASDAQ:NLSP

Does NLS Pharmaceutics AG pay dividends?

No, NLS Pharmaceutics AG does not pay dividends

What sector is NLS Pharmaceutics AG in?

NLS Pharmaceutics AG is in the Healthcare sector

What industry is NLS Pharmaceutics AG in?

NLS Pharmaceutics AG is in the Biotechnology industry

What country is NLS Pharmaceutics AG based in?

NLS Pharmaceutics AG is headquartered in Switzerland

When did NLS Pharmaceutics AG go public?

NLS Pharmaceutics AG's initial public offering (IPO) was on January 29, 2021

Is NLS Pharmaceutics AG in the S&P 500?

No, NLS Pharmaceutics AG is not included in the S&P 500 index

Is NLS Pharmaceutics AG in the NASDAQ 100?

No, NLS Pharmaceutics AG is not included in the NASDAQ 100 index

Is NLS Pharmaceutics AG in the Dow Jones?

No, NLS Pharmaceutics AG is not included in the Dow Jones index

When was NLS Pharmaceutics AG's last earnings report?

NLS Pharmaceutics AG's most recent earnings report was on Jan 10, 2024

When does NLS Pharmaceutics AG report earnings?

The date for NLS Pharmaceutics AG's next earnings report has not been announced yet

Should I buy NLS Pharmaceutics AG stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions